Following a recent R&D Day, where Evaxion presented its AI-Immunology platform, the company released an update on the phase 2 clinical trials of the first patient to complete dosing with personalized cancer vaccine EVX-01.
Evaxion, a leading biotech company, presented its AI-Immunology™ platform at an R&D Day on March 19, 2024. This platform utilizes advanced AI and machine learning to revolutionize the discovery, design, and development of vaccines and immunotherapies. Their platform is modular, scalable, and adaptable to accommodate the requirements and preferences of partners, with established collaborations including vaccine development with MSD (Merck & Co., Inc.).
Key sections of their platform include PIONEER™ & ObsERV™ for cancer immunotherapy, EDEN™ for bacterial vaccine targets, and RAVEN™ for viral pathogens. Evaxion’s AI-driven approach represents a transformative shift in the healthcare landscape, promising to reshape the future of immunotherapy and combat diseases with unparalleled precision and efficacy.
Founded in 2008 and based in Horsholm, Denmark, Evaxion has been a medical landmark for building a bridge between AI technology, bioinformatics, and drug development to bring novel immunotherapies to patients.
WATCH a video interview with BioStock and Evaxion CEO Christian Kanstrup who discusses his vision for Evaxion, delving into AI, cancer, and partnerships.
Advancing Precision Cancer Immunotherapy: PIONEER™ & ObsERV™ in Action
PIONEER™ & ObsERV™ form a powerful alliance in cancer immunotherapy, employing state-of-the-art technologies to combat cancer with precision. PIONEER™ specializes in unlocking the potential of neoantigens, tumor-specific targets arising from cancer cell mutations. Through advanced computational AI models, PIONEER™ accurately identifies patient-specific neoantigen targets, prioritizing those most likely to induce a robust T-cell response and anti-tumor effect. This personalized approach aims to train the patient’s immune system to selectively eradicate tumor cells while minimizing harm to healthy tissue, integrating DNA sequencing and RNA expression data from tumor biopsies to tailor therapeutic neoantigens to individual patients’ needs.
ObsERV™, on the other hand, explores endogenous retroviruses (ERVs) as additional sources of cancer antigens, complementing neoantigen-based immunotherapies. Leveraging a bioinformatics model, ObsERV™ identifies ERVs from sequencing data and designs personalized ERV antigen treatments, enriching Evaxion’s personalized cancer immunotherapy pipeline. As discussions with regulatory authorities progress to incorporate ERV targets into future clinical trials, Evaxion reaffirms its dedication to advancing precision medicine in cancer treatment.
WATCH a video presentation of the latest confirmatory EVX-01 clinical data with key opinion leader Adnan Khattak.
Revolutionizing Vaccine Discovery: Unleashing the Potential of EDEN™
EDEN™ (Efficacy Discriminative Educated Network) stands at the forefront of vaccine discovery, offering unprecedented precision in targeting bacterial pathogens. As antibiotic resistance poses a growing threat, EDEN™ utilizes innovative AI technology to identify antigens capable of eliciting robust, protective immune responses in patients. By ranking these antigens based on their efficacy, EDEN™ accelerates the identification of promising candidates for further (pre-)clinical development, revolutionizing the vaccine discovery process.
At the core of EDEN™ lies a proprietary machine-learning ensemble of AI models, meticulously trained on curated data sets to discern protective antigens from non-protective ones. This technology enables rapid antigen identification in as little as 48 hours, a monumental advancement in the face of increasingly resistant bacterial infections. EDEN™’s ability to predict novel vaccine targets, optimize antigen properties, and leverage genomic sequencing data ensures broad protection against diverse bacterial strains. With current product candidates such as EVX-B1 and EVX-B2 demonstrating promising efficacy against pathogens like S. aureus and antibiotic-resistant Neisseria gonorrhoea, EDEN™ heralds a new era in vaccine development, offering scalable solutions to combat emerging infectious threats.
Redefining Viral Vaccine Development: RAVEN™’s Adaptive Approach
RAVEN™ (Rapidly Adaptive Viral Response) heralds a paradigm shift in vaccine development, offering unparalleled versatility in targeting viral pathogens.
Leveraging a sophisticated blend of evolutionary and structural capabilities, RAVEN™ extends beyond conventional methods by not only identifying viral B-cell antigens but also pinpointing multiple T-cell epitopes. This unique approach ensures the elicitation of a robust and enduring immune response, promising a broader and more reliable vaccine coverage against diverse viral strains.
With the ability to tailor responses to specific viral variants or human populations, RAVEN™ represents a formidable tool in combating infectious diseases with both precision and agility. RAVEN™’s innovative methodology is powered by advanced AI components, enabling the prediction and combination of T-cell epitopes that encompass the immunological diversity of human populations.
By selecting epitopes from the entire viral genome, RAVEN™ ensures comprehensive coverage across different stages of viral replication and minimizes the impact of mutations on vaccine efficacy.
Furthermore, RAVEN™’s delivery model agnosticism and capability to generate cross-reactive neutralizing antibodies from minimal constructs underscore its versatility and applicability across a wide range of viral targets. With EVX-V1 as a promising candidate against Cytomegalovirus (CMV), RAVEN™ paves the way for next-generation vaccines that offer enhanced protection and resilience against evolving viral threats.
Phase 2 Clinical Trial Update: Completion of 1st Patient’s Dosing for Personalized Cancer Vaccine EVX-01
Evaxion Biotech A/S (NASDAQ: EVAX) reports significant progress in its Phase 2 clinical trial as the first patient completes dosing with the personalized cancer vaccine EVX-01. Administered in combination with KEYTRUDA® (pembrolizumab), the EVX-01 vaccine, designed using Evaxion’s proprietary AI-Immunology™ platform, aims to induce a tumor-specific immune response in metastatic melanoma patients.
This milestone underscores Evaxion’s commitment to advancing precision medicine, with each patient receiving a unique vaccine tailored to their individual tumor profile and immune system characteristics. With the trial proceeding as planned, Evaxion anticipates reporting one-year clinical efficacy data in Q3 2024, marking a significant step forward in bringing novel personalized cancer therapies to market.
